Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

Item

http://www.wikidata.org/entity/Q35563832

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Outcomes of Patients With Chro ...... After Transplantation Failure

@ast

Outcomes of Patients With Chro ...... After Transplantation Failure

@en

type

Item

label

Outcomes of Patients With Chro ...... After Transplantation Failure

@ast

Outcomes of Patients With Chro ...... After Transplantation Failure

@en

prefLabel

Outcomes of Patients With Chro ...... After Transplantation Failure

@ast

Outcomes of Patients With Chro ...... After Transplantation Failure

@en

P1476

Outcomes of Patients With Chro ...... After Transplantation Failure

@en

P2093

Chitra Hosing

http://www.w3.org/2001/XMLSchema#string

Elizabeth Shpall

http://www.w3.org/2001/XMLSchema#string

Issa F Khouri

http://www.w3.org/2001/XMLSchema#string

Jan A Burger

http://www.w3.org/2001/XMLSchema#string

Ohad Benjamini

http://www.w3.org/2001/XMLSchema#string

Philip A Thompson

http://www.w3.org/2001/XMLSchema#string

Preetesh Jain

http://www.w3.org/2001/XMLSchema#string

Richard Champlin

http://www.w3.org/2001/XMLSchema#string

Uri Rozovski

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellu

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

The hyper-CVAD regimen in adult acute lymphocytic leukemia.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.

Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.

P304

1557-1563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2014.58.6750

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25847930

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

4417727

http://www.w3.org/2001/XMLSchema#string